Journal article icon

Journal article

Inhibiting ex-vivo Th17 responses in Ankylosing Spondylitis by targeting Janus kinases

Abstract:
Treatment options for Ankylosing Spondylitis (AS) are still limited. The T helper cell 17 (Th17) pathway has emerged as a major driver of disease pathogenesis and a good treatment target. Janus kinases (JAK) are key transducers of cytokine signals in Th17 cells and therefore promising targets for the treatment of AS. Here we investigate the therapeutic potential of four different JAK inhibitors on cells derived from AS patients and healthy controls, cultured in-vitro under Th17-promoting conditions. Levels of IL-17A, IL-17F, IL-22, GM-CSF and IFNγ were assessed by ELISA and inhibitory effects were investigated with Phosphoflow. JAK1/2/3 and TYK2 were silenced in CD4+ T cells with siRNA and effects analyzed by ELISA (IL-17A, IL-17F and IL-22), Western Blot, qPCR and Phosphoflow. In-vitro inhibition of CD4+ T lymphocyte production of multiple Th17 cytokines (IL-17A, IL-17F and IL-22) was achieved with JAK inhibitors of differing specificity, as well as by silencing of JAK1-3 and Tyk2, without impacting on cell viability or proliferation. Our preclinical data suggest JAK inhibitors as promising candidates for therapeutic trials in AS, since they can inhibit multiple Th17 cytokines simultaneously. Improved targeting of TYK2 or other JAK isoforms may confer tailored effects on Th17 responses in AS.
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Oxford college:
St Edmund Hall
Role:
Author
More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
NDORMS
Role:
Author


More from this funder
Funding agency for:
Ridley, A
Bowness, P
Grant:
Oxford Biomedical Research Centre
More from this funder
Funding agency for:
Hammitzsch, A
Grant:
HA-7021/1-1
More from this funder
Grant:
MHA 102288/Z/13/Z


Publisher:
Springer Nature
Journal:
Scientific Reports More from this journal
Publication date:
2018-10-23
Acceptance date:
2018-09-07
DOI:
EISSN:
2045-2322
ISSN:
2045-2322


Pubs id:
pubs:927481
UUID:
uuid:2420862b-2a77-4e50-8603-f95b8f56b757
Local pid:
pubs:927481
Deposit date:
2018-10-15

Terms of use



Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP